AL-GHANDOUR, A., YOUSEF, A., MOHAMED, R., TEALEB, A., AHMED, H., ATWA, H., FARAG, T. (2020). PROPHYLACTIC ANTICRYPTOSPORIDIAL ACTIVITY OF ATORVASTATIN VERSUS NITAZOXANIDE ON EXPERIMENTALLY INFECTED IMMUNOSUPPRESSED MURINE MODELS. Journal of the Egyptian Society of Parasitology, 50(3), 535-546. doi: 10.12816/jesp.2020.131084
ASMAA M. FAROUK AL-GHANDOUR; ASMAA MOHAMMED YOUSEF; RASHA M. S. M. MOHAMED; AL-SAYED M. TEALEB; HYTHAM K. AHMED; HANAA A. ATWA; TAHANI ISMAIL FARAG. "PROPHYLACTIC ANTICRYPTOSPORIDIAL ACTIVITY OF ATORVASTATIN VERSUS NITAZOXANIDE ON EXPERIMENTALLY INFECTED IMMUNOSUPPRESSED MURINE MODELS". Journal of the Egyptian Society of Parasitology, 50, 3, 2020, 535-546. doi: 10.12816/jesp.2020.131084
AL-GHANDOUR, A., YOUSEF, A., MOHAMED, R., TEALEB, A., AHMED, H., ATWA, H., FARAG, T. (2020). 'PROPHYLACTIC ANTICRYPTOSPORIDIAL ACTIVITY OF ATORVASTATIN VERSUS NITAZOXANIDE ON EXPERIMENTALLY INFECTED IMMUNOSUPPRESSED MURINE MODELS', Journal of the Egyptian Society of Parasitology, 50(3), pp. 535-546. doi: 10.12816/jesp.2020.131084
AL-GHANDOUR, A., YOUSEF, A., MOHAMED, R., TEALEB, A., AHMED, H., ATWA, H., FARAG, T. PROPHYLACTIC ANTICRYPTOSPORIDIAL ACTIVITY OF ATORVASTATIN VERSUS NITAZOXANIDE ON EXPERIMENTALLY INFECTED IMMUNOSUPPRESSED MURINE MODELS. Journal of the Egyptian Society of Parasitology, 2020; 50(3): 535-546. doi: 10.12816/jesp.2020.131084
PROPHYLACTIC ANTICRYPTOSPORIDIAL ACTIVITY OF ATORVASTATIN VERSUS NITAZOXANIDE ON EXPERIMENTALLY INFECTED IMMUNOSUPPRESSED MURINE MODELS
This study investigated the possible prophylactic and curative role of Atorvastatin (ATV) in treatment of cryptosporidiosis in immunosuppressed cases. Immunosuppression was done using oral dexamethasone (0.25μg/g/day) for 14 days before infection till last scarification. The study included 150 immunosuppressed mice in 5 major groups (N=30): G1: Normal control group, G2: Infected control group, G3: ATV (40mg/kg/day), G4: Nitazoxanide (NTZ; 500- mg/kg/day), G5: combination group. Each one was divided into 3 subgroups of 10 mice each: prophylaxis ones received drug daily for 5 consecutive days before infection only, 1st and 2nd therapeutic dose groups: mice received the drug for 1 week and 2 weeks after prophylaxis and infection, respectively. Assessment was done parasitological by formol-ether concentration and Modified Ziehl-Neelsen staining of stool pellets gathered weekly, immunological by serum IFN-ɣ levels and histopathological by haematoxyline and eosin staining to determine the drug regimens and parasite impacts on tissues. The results showed a significant reduction in inflammatory changes of ileum, stomach and liver histopathology and in oocysts shed on the 7th day post infection (PI) by 62.08%, 40.55% & 71.78%, on the 14th day (PI) by 78.53%, 53.4%, 87.43% & 90.41%, 57.21%, 94.71% on 21st day (PI) in all treated groups respectively, compared to infected untreated control ones. Sera IFN-ɣ levels showed significant increase in combination followed by ATV prophylactic drug regimens compared to NTZ alone or infected control ones. Combined ATV and NTZ prophylaxis gave a good synergistic anticryptosporidial efficacy in immunosuppressed mice.